Aterian (ATER) $18M Asset Sale: Cash Distribution Setup with a Tariff-Refund CVR

The Deal

Aterian, Inc. (NASDAQ: ATER) is a small-cap consumer products company that owns a portfolio of e-commerce brands sold primarily through Amazon. On April 28, 2026, the company announced two simultaneous transactions that together amount to a wind-down and reverse-merger: an $18.0 million asset sale to Trademark Global and a $7.0 million preferred-stock investment from David Lazar.

The asset sale covers Aterian's entire operating portfolio — Mueller Living, PurSteam, hOmeLabs, Squatty Potty, Healing Solutions, and Photo Paper Direct — for $18.0 million in cash, subject to working capital and other adjustments. Trademark Global will onboard the majority of supporting employees. Excluded from the deal: cash, certain Amazon accounts, intellectual property, corporate records, tax assets, and any indebtedness — those stay with Aterian.

The Lazar piece is structured as two preferred tranches. The first $3.5 million Series AA tranche closed April 27, 2026; the $3.5 million Series AAA tranche closes simultaneously with the asset sale, contingent on stockholder approval. After both close, Lazar will hold approximately 95.13% of the company on a fully-diluted basis and will become CEO. Crucially, per the Form 8-K filed April 29, 2026, Lazar and his affiliates contractually waived rights to the asset sale proceeds and to the CVR — meaning existing common holders capture 100% of those distributions.

Why This Matters

This is not a tender offer or a clean buyout. It's structured as a corporate reset where existing holders get cashed out via a dividend rather than at the share register. That makes it closer to a partial liquidation than a merger arb, and it's worth a careful look at the current price.

ATER closed at $0.657 on April 27 — the last unaffected day. The announcement landed after the close, the stock surged 122% the next day, and printed a $2.19 intraday high in the days that followed before retracing to $0.95 as of April 30, 2026. The market got excited, then started pricing in deductions.

There are two distinct cash pools, and only one of them goes to existing common shareholders. The asset sale net proceeds will be distributed to common holders. The company's existing balance-sheet cash — $4.9 million of unrestricted cash as of December 31, 2025, almost certainly lower today after Q1 2026 burn — stays with the post-deal Lazar shell. Lazar's $7 million preferred is structurally there to capitalize that shell. So when modeling per-share distribution, only the asset sale waterfall counts.

The Per-Share Math

The deal mechanics published so far don't quantify the distribution, but the source data lets me build a rough range.

The $1–3M deduction line for working capital adjustments and retained reserves is doing real work in that spread — direction unknown, and the proxy statement (expected in early May) is what tightens this as Aterian will have to disclose an estimated distribution range there. Until then, anyone modeling specific numbers is working from incomplete data.

At $0.95 today, you're paying in the lower-middle of that estimated distribution range — roughly 32% of the way through the base-case spread. If the distribution lands at the midpoint of about $1.02 and you wait the four-to-five months to Q3 2026, that's a 7% return before any contribution from the CVR. If it lands at $1.05, the return is 10.5% — annualized, roughly 25-30%. If it lands at $1.20 (the top of the base range), the return jumps to 26%. If it lands at $0.85 (near the bottom), you're down about 10% before the CVR provides any cushion. The cash distribution alone has positive expected value if proceeds clear the midpoint, with the CVR providing additional optionality on top.

The CVR — Where the Upside Lives

The CVR is more concrete than the headlines suggest. It covers two pools: tariff refunds dating from 2025 forward, and proceeds from the liquidation of any remaining excluded assets.

The tariff piece is the interesting one. From Aterian's FY2025 10-K filed March 23, 2026:

"On August 29, 2025, the U.S. Court of International Trade ruled... that the International Emergency Economic Powers Act (IEEPA) does not authorize the President to impose tariffs. This ruling effectively invalidated several tariff regimes in effect during 2025 under which the Company paid significant duties. While this decision may entitle the Company to refunds for previously paid IEEPA tariffs, the timing and process for such refunds remain uncertain, and no asset has been recognized as of December 31, 2025."

That last clause matters. Aterian paid "significant duties" under IEEPA in 2025, the court invalidated the underlying authority, and the company's accountants did not capitalize the potential refund as an asset. With Aterian's 2025 direct net revenue down $31.6 million (32.4%) on tariff-driven price increases, the underlying tariff cost base in 2025 was meaningful — even partial refunds could translate to a real per-share contribution to the CVR. The company hasn't published a tariff dollar figure, so any specific number here is speculative.

The Section 122 baseline 10% tariff effective February 24, 2026 is similarly time-limited (150 days unless extended). If that structure is challenged the same way IEEPA was, additional refunds could feed the CVR pool. The CVR is non-transferable, so whatever it pays, you're holding it through whenever the customs adjudication completes — which could stretch for years.

Key Terms

• Vote required by July 20, 2026. Approval items include the asset sale, common-stock issuance on conversion of Lazar's preferred, an authorized share increase from 500 million to 1 billion shares, election of four Lazar director designees, and a reverse stock split in a 1-for-2 to 1-for-99 range.
• Lazar waived distribution rights. Asset sale proceeds and CVR distributions go entirely to existing common holders.
• No financing condition on the asset sale. Trademark Global is funding from its own resources.
• Closing condition with teeth: the company must achieve contribution margins of 87.5% or higher during specified measurement periods. A miss gives the buyer a walk right.
• Termination fee: $1,080,000 in defined termination scenarios. Buyer expense reimbursement capped at $600,000.
• Voting agreement locks up directors and officers in favor of the transaction. They represent a small fraction of the float.
• Going concern flagged. Aterian's independent registered public accounting firm included an explanatory paragraph in its FY2025 audit report raising substantial doubt about the company's ability to continue as a going concern.

Timeline

Risks

• Vote risk. Approval requires affirmative votes on multiple items (asset sale, authorized share increase, director election, reverse split). Insiders are locked up but represent a small fraction of the float, and ATER has a heavy retail base. A "no" on any item could derail the structure.
• Contribution margin condition. The 87.5% threshold is a closing condition the buyer can fall back on. For a business in run-off mode burning through inventory, there is real risk of a margin miss before close.
• Working capital adjustments. The "$18 million base, subject to adjustments" language is doing meaningful work in the price. Final cash to the company could come in materially below $18 million if working capital settles unfavorably.
• Cash burn between signing and close. Aterian's stockholders' equity dropped from $22.6M (Sept 2025) to $15.2M (Dec 2025). Operating losses are eating real money. Any extended timeline shrinks the distribution pool dollar-for-dollar.
• Going concern. The auditor's substantial-doubt language is not boilerplate. If the deal terminates, the downside scenario is genuinely ugly — Aterian had only $4.9 million of unrestricted cash and $0.2 million of credit facility availability as of December 31, 2025.
• CVR is non-transferable and unquantified. Tariff refund timing depends on customs adjudication that can stretch for years. Don't assign a specific value here without conviction.
• Residual stub is essentially worthless near-term. The 4.87% post-deal stake in a Lazar shell is a free option, not a base case.

The Bottom Line

This is a contingent cash distribution play, not a tender offer. At $0.95, you are paying in the lower-middle of the base-case distribution range, leaving positive expected return on the cash distribution alone if proceeds clear the midpoint, with the CVR providing additional optionality. The proxy filing in early May is the next material catalyst — that is when the per-share math gets real. Until then, the spread is real but the contingencies are real too.

This analysis is for informational purposes only and does not constitute investment advice. Read the complete 8-K filing and consult your own advisors before making any decisions.